Rheumatoid Awareness Day: It Is Also An Immune System Disease
Rheumatoid Awareness Day, initiated by the Rheumatoid Patient Foundation, is held every year on February 2, to raise awareness for patients with rheumatoid arthritis.
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that primarily affects the joints. The joint destruction in rheumatoid arthritis is mediated by cytokines, chemokines and metalloproteinases. Symmetric peripheral arthritis (e.g., wrist and metacarpophalangeal joints) is the main feature of rheumatoid arthritis, with progressive destruction of affected joint structures and often associated with systemic symptoms. Diagnosis relies on specific clinical manifestations, laboratory tests and imaging features. Treatment includes medications, functional exercises, and sometimes surgery. Anti-rheumatic drugs that improve the condition help control symptoms and slow disease progression.
Rheumatoid arthritis is distributed worldwide, with a prevalence of 0.1% to 1.9% in different populations. Rheumatic disease has become a major disease that causes labor loss. But in fact, joint disease is not terrible, as long as early detection, early treatment, and the use of correct medical methods, patients with rheumatoid disease can completely recover.
Attachments:
Next Page
MORE NEWS
n November 18, 2025, YHLO’s 2025 Global Core Distributors Conference was successfully held in Düsseldorf, Germany. Under the theme “Academia-Driven, Shared Value,” the meeting brought together representatives from more than 30 core distributors worldwide. YHLO’s founder, Mr. Deming Hu, and Chairman, Mr. Kunhui Hu, led the company’s executive team to attend and discuss strategic development with partners.
2025-11-20
YHLO Secures Approval for the World’s First sCD146 CLIA Assay
YHLO has obtained approval from the Guangdong Medical Products Administration for its soluble CD146 (sCD146) CLIA assay, marking a major milestone in central nervous system (CNS) disease diagnostics. YHLO is now the first company worldwide to offer an sCD146 test for cerebrospinal fluid, bringing its total CLIA assay portfolio in China to 173.
2025-11-18
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
